Pfizer to submit US emergency use application for its COVID-19 vaccine
Pfizer has announced that it will today be applying for emergency use authorisation (EUA) of its Covid-19 vaccine, days after final results of the Phase III trial were announced, showing it was 95% effective in preventing Covid-19.
Source:
Reuters Health
SPS commentary:
The MHRA will be rigorously assessing the evidence of the vaccine’s safety and efficacy once it has received the full results of the trials.